- 专利标题： Substituted pyrrolidine compound and use thereof
-
申请号： US16491811申请日： 2018-03-07
-
公开(公告)号： US11059780B2公开(公告)日： 2021-07-13
- 发明人: Masaki Daini , Yuhei Miyanohana , Satoshi Mikami , Yuichi Kajita , Masaki Ogino , Tatsuki Koike , Kohei Takeuchi
- 申请人： Takeda Pharmaceutical Company Limited
- 申请人地址： JP Osaka
- 专利权人： Takeda Pharmaceutical Company Limited
- 当前专利权人： Takeda Pharmaceutical Company Limited
- 当前专利权人地址： JP Osaka
- 代理机构： Foley & Lardner LLP
- 优先权： JPJP2017-044249 20170308
- 国际申请： PCT/JP2018/008811 WO 20180307
- 国际公布： WO2018/164191 WO 20180913
- 主分类号： C07D207/12
- IPC分类号： C07D207/12 ; C07D405/12 ; C07D403/12 ; C07D405/14 ; C07D401/14 ; C07D417/14 ; C07D403/14 ; C07D493/08 ; C07D487/10 ; C07D498/10 ; C07D471/04 ; C07D413/12 ; C07D491/107 ; C07D487/08
摘要：
The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.